Top Abstract Purchase Related
Home
>
Node
>
Subnode

High on-treatment platelet reactivity in patients with chronic renal failure using acetylsalicylic acid

Horyniecki, M.; Łącka-Gaździk, B.; Dworaczek, W.; Śnit, M.ła.; Łabuz-Roszak, B.

Wiadomosci Lekarskie 70(6 Part 1): 1102-1107

2017

ISSN/ISBN: 0043-5147
PMID: 29478986
Document Number: 692744
Cardiovascular diseases (CVD) are the most common cause of mortality in the world. Acetylsalicylic acid (ASA) is a widely used medicine in primary and secondary prevention of cardiovascular diseases. About 1-60% patients taking aspirin have high platelet reactivity (HOPR) despite aspirin treatment. HOPR is significantly more frequent in patients with chronic kidney disease (CKD) and it increases the risk of adverse cardiovascular events in these patients. The cause of HOPR in patients with CKD may be oxidative stress and inflammation. To the risk factors belong diabetes, female sex or decreased HDL cholesterol level.

Document emailed within 1 workday
Secure & encrypted payments

Peters, F.T.; Booij, A.C.; van der Graaf, F.; Vader, H.L.; Gerlag, P.G. 1987: Influence of low-dose acetylsalicylic acid on platelet function in patients on renal replacement therapy Netherlands Journal of Medicine 31(5-6): 210-217
Phankingthongkum, R.; Panchavinnin, P.; Chinthammitr, Y.; Tresukosol, D.; Chotinaiwattarakul, C.; Tungsubutra, W.; Wongpraparut, N.; Kitrattana, B.; Leewanun, P. 2013: High on-clopidogrel treatment platelet reactivity in Thai patients with chronic stable angina scheduled for percutaneous coronary intervention Journal of the Medical Association of Thailand 96(5): 538-543
Rud'ko, I.A.; Chebotarev, V.N.; Kubatiev, A.A. 1994: Local microviscosity of platelet membranes from patients with chronic renal failure on hemodialysis Patologicheskaia Fiziologiia i Eksperimental'naia Terapiia 1: 20-22
Luo, N.; Meng, J.; Yang, D.; Wu, C.; Qi, F.; Kong, L.; Liu, W. 1999: Expression and significance of neuropeptide and neurotensin in the extract of platelet of chronic renal failure patients during hemodialysis Sheng Wu Yi Xue Gong Cheng Xue Za Zhi 16(3): 362-364; 381
Tungsanga, K.; Kateruttanakul, P.; Sitprija, V. 1988: The renal handling of urate in acute renal failure patients with high urine uric acid/urine creatinine concentration ratio Journal of the Medical Association of Thailand 71(1): 29-32
Bergström, J.; Ahlberg, M.; Alvestrand, A.; Fürst, P. 1987: Amino acid therapy for patients with chronic renal failure Infusionstherapie und Klinische Ernahrung 14(Suppl): 8-11
Lindsay, R.M.; Moorthy, A.V.; Koens, F.; Linton, A.L. 1975: Platelet function in dialyzed and non-dialyzed patients with chronic renal failure Clinical Nephrology 4(2): 52-57
Wu, E.B.; Witherspoon, M.L.; Gillmore, J.D.; Pattison, J.M.; Chambers, J.B. 1997: The role of transesophageal echocardiography in patients with chronic renal failure at low and high risk of endocarditis Journal of Heart Valve Disease 6(3): 249-252
Heinrich, D.; Maier, K.P. 1995: Treatment of chronic virus hepatitis with acetylsalicylic acid Schweizerische Medizinische Wochenschrift 125(15): 755-757
Lasierra Cirujeda, J.; Sánchez Casajus, A.; Vilades Juan, E. 1980: Platelet factor 3 (P-F-3) in chronic renal failure. Effect of dialysis Revista Clinica Espanola 156(5): 321-324
Stenver, D.; Jeppesen, L.; Nielsen, B.; Dalsgaard Nielsen, J.; Haedersdal, C.; Mehlsen, J.; Winther, K. 1994: The effect of erythropoietin on platelet function and fibrinolysis in chronic renal failure International Journal of Artificial Organs 17(3): 141-145
González, F. 2003: Implementation of AUGE plan for chronic renal failure patients. The implementation of Universal Access and Explicit Guaranties Plan (AUGE), generates longer waiting lists among patients with chronic renal failure Revista Medica de Chile 131(5): 545-551
Guzzo, J.; Niewiarowski, S.; Musial, J.; Bastl, C.; Grossman, R.A.; Rao, A.K.; Berman, I.; Paul, D. 1980: Secreted platelet proteins with antiheparin and mitogenic activities in chronic renal failure Journal of Laboratory and Clinical Medicine 96(1): 102-113
Gin, H.; Perlemoine, C.; Raffaitin, C.; Rigalleau, V. 2006: Treatment of type Ii diabetic patients with chronic renal failure Nephrologie and Therapeutique 2(Suppl 1): S59-S62
Marczewski, K.; Wójcik, J.; Janicka, L.; Bednarek-Skublewska, A.; Prasał, M.; Markiewicz, M. 1990: Arrhythmia in patients on dialysis treatment for chronic renal failure Wiadomosci Lekarskie 43(8): 313-317
Gołkiewicz, W.; Bartos, A. 1993: Determination of trace amounts of salicylic acid and acetylsalicylic acid in polopirin and other drugs containing acetylsalicylic acid Acta Poloniae Pharmaceutica 50(2-3): 143-147
Hardin, T.C.; Butler, S.C.; Ross, S.; Wakeford, J.H.; Jorgensen, J.H. 1994: Comparison of ampicillin-sulbactam and ticarcillin-clavulanic acid in patients with chronic renal failure: effects of differential pharmacokinetics on serum bactericidal activity PharmacoTherapy 14(2): 147-152
Born, G.V.; Görög, P.; Begent, N.A. 1984: Experimental basis of platelet aggregation inhibition by acetylsalicylic acid Folia Haematologica 111(6): 719-724
Klinger, M.; Szewczyk, Z.; Kazimierczak, K.; Kramarz, S. 1990: Cefoperazone--Possibility of safer treatment for infections in patients with chronic renal failure Wiadomosci Lekarskie 43(15-16): 773-776
Chorváthová, V.; Dzúrik, R.; Ondreicka, R.; Ozdín, L.; Nemec, R.; Cerveń, J. 1976: Effect of glucose utilization inhibitor isolated from the serum and urine of patients with chronic renal failure on the free fatty acid metabolism in rat kidney cortex slices Physiologia Bohemoslovaca 25(2): 123-127